Milaneschi Yuri, Lamers Femke, Peyrot Wouter J, Baune Bernhard T, Breen Gerome, Dehghan Abbas, Forstner Andreas J, Grabe Hans J, Homuth Georg, Kan Carol, Lewis Cathryn, Mullins Niamh, Nauck Matthias, Pistis Giorgio, Preisig Martin, Rivera Margarita, Rietschel Marcella, Streit Fabian, Strohmaier Jana, Teumer Alexander, Van der Auwera Sandra, Wray Naomi R, Boomsma Dorret I, Penninx Brenda W J H
Department of Psychiatry, Amsterdam Public Health and Amsterdam Neuroscience, Vrije Universiteit Medical Center and GGZ inGeest, Amsterdam, the Netherlands.
Discipline of Psychiatry, University of Adelaide, Adelaide, Australia.
JAMA Psychiatry. 2017 Dec 1;74(12):1214-1225. doi: 10.1001/jamapsychiatry.2017.3016.
The association between major depressive disorder (MDD) and obesity may stem from shared immunometabolic mechanisms particularly evident in MDD with atypical features, characterized by increased appetite and/or weight (A/W) during an active episode.
To determine whether subgroups of patients with MDD stratified according to the A/W criterion had a different degree of genetic overlap with obesity-related traits (body mass index [BMI] and levels of C-reactive protein [CRP] and leptin).
DESIGN, SETTING, AND PATIENTS: This multicenter study assembled genome-wide genotypic and phenotypic measures from 14 data sets of the Psychiatric Genomics Consortium. Data sets were drawn from case-control, cohort, and population-based studies, including 26 628 participants with established psychiatric diagnoses and genome-wide genotype data. Data on BMI were available for 15 237 participants. Data were retrieved and analyzed from September 28, 2015, through May 20, 2017.
Lifetime DSM-IV MDD was diagnosed using structured diagnostic instruments. Patients with MDD were stratified into subgroups according to change in the DSM-IV A/W symptoms as decreased or increased.
Data included 11 837 participants with MDD and 14 791 control individuals, for a total of 26 628 participants (59.1% female and 40.9% male). Among participants with MDD, 5347 (45.2%) were classified in the decreased A/W and 1871 (15.8%) in the increased A/W subgroups. Common genetic variants explained approximately 10% of the heritability in the 2 subgroups. The increased A/W subgroup showed a strong and positive genetic correlation (SE) with BMI (0.53 [0.15]; P = 6.3 × 10-4), whereas the decreased A/W subgroup showed an inverse correlation (-0.28 [0.14]; P = .06). Furthermore, the decreased A/W subgroup had a higher polygenic risk for increased BMI (odds ratio [OR], 1.18; 95% CI, 1.12-1.25; P = 1.6 × 10-10) and levels of CRP (OR, 1.08; 95% CI, 1.02-1.13; P = 7.3 × 10-3) and leptin (OR, 1.09; 95% CI, 1.06-1.12; P = 1.7 × 10-3).
The phenotypic associations between atypical depressive symptoms and obesity-related traits may arise from shared pathophysiologic mechanisms in patients with MDD. Development of treatments effectively targeting immunometabolic dysregulations may benefit patients with depression and obesity, both syndromes with important disability.
重度抑郁症(MDD)与肥胖之间的关联可能源于共同的免疫代谢机制,这在具有非典型特征的MDD中尤为明显,其特征是在活跃发作期间食欲和/或体重(A/W)增加。
确定根据A/W标准分层的MDD患者亚组与肥胖相关性状(体重指数[BMI]、C反应蛋白[CRP]水平和瘦素水平)的遗传重叠程度是否不同。
设计、设置和患者:这项多中心研究收集了精神基因组学联盟14个数据集的全基因组基因型和表型数据。数据集来自病例对照、队列和基于人群的研究,包括26628名有既定精神疾病诊断和全基因组基因型数据的参与者。15237名参与者有BMI数据。数据于2015年9月28日至2017年5月20日检索和分析。
使用结构化诊断工具诊断终生DSM-IV MDD。根据DSM-IV A/W症状的变化(减少或增加)将MDD患者分层为亚组。
数据包括11837名MDD参与者和14791名对照个体,共26628名参与者(59.1%为女性,40.9%为男性)。在MDD参与者中,5347名(45.2%)被归类为A/W减少亚组,1871名(15.8%)被归类为A/W增加亚组。常见遗传变异解释了这两个亚组中约10%的遗传力。A/W增加亚组与BMI呈现强正遗传相关性(SE)(0.53[0.15];P = 6.3×10-4),而A/W减少亚组呈现负相关(-0.28[0.14];P = 0.06)。此外,A/W减少亚组BMI增加、CRP水平和瘦素水平的多基因风险更高(优势比[OR],1.18;95%置信区间,1.12 - 1.25;P = 1.6×10-10)、(OR,1.08;95%置信区间,1.02 - 1.13;P = 7.3×10-3)和(OR,1.09;95%置信区间,1.06 - 1.12;P = 1.7×10-3)。
非典型抑郁症状与肥胖相关性状之间的表型关联可能源于MDD患者共同的病理生理机制。开发有效针对免疫代谢失调的治疗方法可能使抑郁症和肥胖患者受益,这两种综合征都具有重要的致残性。